Myovant Shares Jump Premarket on FDA Expanded OK of Myfembree
08 August 2022 - 12:53PM
Dow Jones News
By Colin Kellaher
Shares of Myovant Sciences Ltd. rose more than 15% in premarket
trading Monday after the biopharmaceutical company and partner
Pfizer Inc. won U.S. Food and Drug Administration expanded approval
of Myfembree for the management of moderate to severe pain
associated with endometriosis in premenopausal women.
The FDA had been slated to act on the application for expanded
approval in early May but extended its review after the companies
submitted more information regarding bone mineral density at the
agency's request.
The agency last year approved Myfembree for the management of
heavy menstrual bleeding associated with uterine fibroids in
premenopausal women. Myovant and Pfizer are jointly developing and
commercializing Myfembree.
Myovant shares, which closed Friday at $15.12, were recently up
at $17.50 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 08, 2022 06:38 ET (10:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
